Bone health in pediatric patients with neurological disorders

키워드

참고문헌 (98)

1. Ward LM, "The management of osteoporosis in children", Osteoporos Int, 27, pp.2147~2179 (2016)
2. Houlihan CM, "Bone density in cerebral palsy", Phys Med Rehabil Clin N Am, 20, pp.493~508 (2009)
3. Bonjour JP, "Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence", J Clin Endocrinol Metab, 73, pp.555~563 (1991)
4. Melton LJ 3rd, "Lifetime fracture risk : an approach to hip fracture risk assessment based on bone mineral density and age", J Clin Epidemiol, 41, pp.985~994 (1988)
5. Henderson RC, "Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy", Pediatrics, 110(1 Pt 1), pp.e5~ (2002)
6. McNamara NA, "Bone health and endocrine comorbidities in pediatric epilepsy", Semin Pediatr Neurol, 24, pp.301~309 (2017)
7. Yasar E, "Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities", Eur J Paediatr Neurol, 22, pp.17~26 (2018)
8. Gordon CM, "2013 Pediatric Position Development Conference : executive summary and reflections", J Clin Densitom, 17, pp.219~224 (2014)
9. Jones AR, "Bone density assessment in a tertiary paediatric centre over 13years : referral patterns and limitations", J Paediatr Child Health, 51, pp.608~613 (2015)
10. Frost HM, "Bone's mechanostat : a 2003 update", Anat Rec A Discov Mol Cell Evol Biol, 275, pp.1081~1101 (2003)
11. DeLuca HF, "Overview of general physiologic features and functions of vitamin D", Am J Clin Nutr, 80(6Suppl), pp.1689S~1696S (2004)
12. Misra M, "Vitamin D deficiency in children and its management : review of current knowledge and recommendations", Pediatrics, 122, pp.398~417 (2008)
13. Holick MF, "Evaluation, treatment, and prevention of vitamin D deficiency : an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.1911~1930 (2011)
14. Goltzman D, "Functions of vitamin D in bone", Histochem Cell Biol, 149, pp.305~312 (2018)
15. Rosen CJ, "Clinical practice. Vitamin D insufficiency", N Engl J Med, 364, pp.248~254 (2011)
16. Shellhaas RA, "Vitamin D and bone health among children with epilepsy", Pediatr Neurol, 42, pp.385~393 (2010)
17. Mesias M, "Calcium nutrition in adolescence", Crit Rev Food Sci Nutr, 51, pp.195~209 (2011)
18. Blair HC, "Calcium and bone disease", Biofactors, 37, pp.159~167 (2011)
19. Ross AC, "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine : what clinicians need to know", J Clin Endocrinol Metab, 96, pp.53~58 (2011)
20. Cheng JB, "Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase", Proc Natl Acad Sci U S A, 101, pp.7711~7715 (2004)
21. Dawson-Hughes B, "Estimates of optimal vitamin D status", Osteoporos Int, 16, pp.713~716 (2005)
22. Soderpalm AC, "Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy", Neuromuscul Disord, 17, pp.919~928 (2007)
23. Francis RM, "Calcium and vitamin D in the prevention of osteoporotic fractures", Qjm, 99, pp.355~363 (2006)
24. Kilpinen-Loisa P, "Insufficient energy and nutrient intake in children with motor disability", Acta Paediatr, 98, pp.1329~1333 (2009)
25. Mutlu GY, "Prevention of Vitamin D deficiency in infancy : daily 400 IU vitamin D is sufficient", Int J Pediatr Endocrinol, 2011, pp.4~ (2011)
26. Gonzalez L, "Nutrition-related problems of pediatric patients with neuromuscular disorders", P R Health Sci J, 19, pp.35~38 (2000)
27. Aydin K, "High rates of malnutrition and epilepsy : two common comorbidities in children with cerebral palsy", Turk J Med Sci, 49, pp.33~37 (2019)
28. Bailey DA, "Bone tissue and physical activity", Can J Sport Sci, 15, pp.229~239 (1990)
29. Frost HM, "The "muscle-bone unit" in children and adolescents: a 2000 overview", J Pediatr Endocrinol Metab, 13, pp.571~590 (2000)
30. Zacharin M, "Current advances in bone health of disabled children", Curr Opin Pediatr, 16, pp.545~551 (2004)
31. Mergler S, "Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy : a systematic review", Dev Med Child Neurol, 51, pp.773~778 (2009)
32. Zacharin M, "Assessing the skeleton in children and adolescents with disabilities: avoiding pitfalls, maximising outcomes. A guide for the general paediatrician", J Paediatr Child Health, 45, pp.326~331 (2009)
33. Henderson RC, "Bone density and other possible predictors of fracture risk in children and adolescents with spastic quadriplegia", Dev Med Child Neurol, 39, pp.224~227 (1997)
34. Sturm PF, "Femur fractures in institutionalized patients after hip spica immobilization", J Pediatr Orthop, 13, pp.246~248 (1993)
35. Stasikelis PJ, "Complications of osteotomies in severe cerebral palsy", J Pediatr Orthop, 19, pp.207~210 (1999)
36. Henderson RC, "Residual bonemineral density and muscle strength after fractures of the tibia or femur in children", J Bone Joint Surg Am, 74, pp.211~218 (1992)
37. Wong J, "Physical activity in children", teens with epilepsy compared with that in their siblings without epilepsy, 2006, pp.47, 631~639
38. Canalis E, "Mechanisms of glucocorticoid-induced osteoporosis", Curr Opin Rheumatol, 15, pp.454~457 (2003)
39. Verrotti A, "Increased bone turnover in epileptic patients treated with carbamazepine", Ann Neurol, 47, pp.385~388 (2000)
40. Nicholas JM, "Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy:cohort study using the general practice research database", Seizure, 22, pp.37~42 (2013)
41. Verrotti A, "Bone and calcium metabolism and antiepileptic drugs", Clin Neurol Neurosurg, 112, pp.1~10 (2010)
42. Vestergaard P, "Fracture risk associated with use of antiepileptic drugs", Epilepsia, 45, pp.1330~1337 (2004)
43. Riss J, "Benzodiazepines in epilepsy : pharmacology and pharmacokinetics", Acta Neurol Scand, 118, pp.69~86 (2008)
44. Ensrud KE, "Antiepileptic drug use increases rates of bone loss in older women : a prospective study", Neurology, 62, pp.2051~2057 (2004)
45. Kulak CA, "Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs", Arq Neuropsiquiatr, 62, pp.940~948 (2004)
46. Hosseinpour F, "Phenobarbital suppresses vitamin D3 25-hydroxylase expression : a potential new mechanism for drug-induced osteomalacia", Biochem Biophys Res Commun, 357, pp.603~607 (2007)
47. Foss MC, "The effect of the anticonvulsants phenobarbital and diphenylhydantoin on intestinal absorption of calcium", Acta Physiol Lat Am, 29, pp.223~228 (1979)
48. Koch HU, "Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat", Epilepsia, 13, pp.829~834 (1972)
49. Luoma PV, "Changes in serum triglyceride and cholesterol levels during longterm phenytoin treatment for epilepsy", Acta Med Scand, 206, pp.229~231 (1979)
50. Harris M, "Phenytoin inhibition of parathyroid hormone induced bone resorption in vitro", Br J Pharmacol, 50, pp.405~408 (1974)
51. Hahn TJ, "Interaction of diphenylhydantoin(phenytoin)and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro", J Clin Invest, 62, pp.406~414 (1978)
52. Pack AM, "Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy", Neurology, 70, pp.1586~1593 (2008)
53. Valimaki MJ, "Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs", J Bone Miner Res, 9, pp.631~637 (1994)
54. Feldkamp J, "Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells", Exp Clin Endocrinol Diabetes, 108, pp.37~43 (2000)
55. Takahashi A, "Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria", Jpn J Pharmacol, 82, pp.82~84 (2000)
56. Ohta T, "Low dose phenytoin is an osteogenic agent in the rat", Calcif Tissue Int, 56, pp.42~48 (1995)
57. Vernillo AT, "Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17", 2.8 cells in culture, 1990, pp.11, 309~312
58. von Borstel Smith M, "Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells", Toxicol In Vitro, 21, pp.855~862 (2007)
59. Sato Y, "Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy", Neurology, 57, pp.445~449 (2001)
60. Tekgul H, "Bone mineral status in pediatric outpatients on antiepileptic drug monotherapy", J Child Neurol, 21, pp.411~414 (2006)
61. Tsukahara H, "Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy", Pediatr Int, 44, pp.247~253 (2002)
62. Babayigit A, "Adverse effects of antiepileptic drugs on bone mineral density", Pediatr Neurol, 35, pp.177~181 (2006)
63. Andress DL, "Antiepileptic drug-induced bone loss in young male patients who have seizures", Arch Neurol, 59, pp.781~786 (2002)
64. Pack AM, "Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy", Ann Neurol, 57, pp.252~257 (2005)
65. Kim SH, "A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy", Epilepsy Behav, 10, pp.291~295 (2007)
66. Nicolaidou P, "Effects of anticonvulsant therapy on vitamin D status in children : prospective monitoring study", J Child Neurol, 21, pp.205~209 (2006)
67. Boluk A, "The effect of valproate on bone mineral density in adult epileptic patients", Pharmacol Res, 50, pp.93~97 (2004)
68. Kumandas S, "Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3", J Pediatr Endocrinol Metab, 19, pp.529~534 (2006)
69. Rieger-Wettengl G, "Analysis of the musculoskeletal system in children and adolescents receiving anticonvulsant monotherapy with valproic acid or carbamazepine", Pediatrics, 108, pp.E107~ (2001)
70. Guo CY, "Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy", Epilepsia, 42, pp.1141~1147 (2001)
71. Kafali G, "Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12years", Clin Pediatr (Phila), 38, pp.93~98 (1999)
72. Erbayat Altay E, "Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid", J Pediatr Endocrinol Metab, 13, pp.933~939 (2000)
73. Voudris K, "Alkaline phosphatase and its isoenzyme activity for the evaluation of bone metabolism in children receiving anticonvulsant monotherapy", Seizure, 11, pp.377~380 (2002)
74. Oner N, "Bone mineral metabolism changes in epileptic children receiving valproic acid", J Paediatr Child Health, 40, pp.470~473 (2004)
75. Akin R, "Evaluation of bone mineral density in children receiving antiepileptic drugs", Pediatr Neurol, 19, pp.129~131 (1998)
76. Simm PJ, "The effect of the ketogenic diet on the developing skeleton", Epilepsy Res, 136, pp.62~66 (2017)
77. Ali, II, "Antiepileptic drugs and reduced bone mineral density", Epilepsy Behav, 5, pp.296~300 (2004)
78. Farhat G, "Effect of antiepileptic drugs on bone density in ambulatory patients", Neurology, 58, pp.1348~1353 (2002)
79. Lazzari AA, "Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial", Epilepsia, 54, pp.1997~2004 (2013)
80. Gniatkowska-Nowakowska A, "Fractures in epilepsy children", Seizure, 19, pp.324~325 (2010)
81. Valmadrid C, "Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy", Arch Neurol, 58, pp.1369~1374 (2001)
82. Fewtrell MS, "Bone densitometry in children assessed by dual x ray absorptiometry : uses and pitfalls", Arch Dis Child, 88, pp.795~798 (2003)
83. Kossoff EH, "Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group", Epilepsia Open, 3, pp.175~192 (2018)
84. Leet AI, "Fractures in children with cerebral palsy", J Pediatr Orthop, 26, pp.624~627 (2006)
85. Stallings VA, "Body composition in children with spastic quadriplegic cerebral palsy", J Pediatr, 126, pp.833~839 (1995)
86. Fehlings D, "Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis : a systematic review", Dev Med Child Neurol, 54, pp.106~116 (2012)
87. Ozel S, "Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis : an update", Dev Med Child Neurol, 58, pp.918~923 (2016)
88. Larson CM, "Bone mineral density and fractures in boys with Duchenne muscular dystrophy", J Pediatr Orthop, 20, pp.71~74 (2000)
89. McDonald DG, "Fracture prevalence in Duchenne muscular dystrophy", Dev Med Child Neurol, 44, pp.695~698 (2002)
90. King WM, "Orthopedic outcomes of longterm daily corticosteroid treatment in Duchenne muscular dystrophy", Neurology, 68, pp.1607~1613 (2007)
91. Birnkrant DJ, "Diagnosis and management of Duchenne muscular dystrophy, part 2 : respiratory, cardiac, bone health, and orthopaedic management", Lancet Neurol, 17, pp.347~361 (2018)
92. Bianchi ML, "Bone mineral density and bone metabolism in Duchenne muscular dystrophy", Osteoporos Int, 14, pp.761~767 (2003)
93. Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management", Lancet Neurol, 9, pp.77~93 (2010)
94. Ma J, "The time to and determinants of first fractures in boys with Duchenne muscular dystrophy", Osteoporos Int, 28, pp.597~608 (2017)
95. Ferraris JR, "Effects of deflazacort vs. methylprednisone : a randomized study in kidney transplant patients", Pediatr Nephrol, 22, pp.734~741 (2007)
96. Ferraris JR, "Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group", Pediatr Nephrol, 14, pp.682~688 (2000)
97. Loftus J, "Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis:a relatively bone-sparing effect of deflazacort", Pediatrics, 88, pp.428~436 (1991)
98. Singh A, "Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort", J Pediatr Orthop, 38, pp.320~324 (2018)

관련 논문AI추천